The immune response to a meningococcal 200 kDa surface exposed protein following carriage and disease

R. Borrow; A. J. Fox; D. M. Jones

doi:10.1016/S0888-0786(96)01075-X

The immune response to a meningococcal 200 kDa surface exposed protein following carriage and disease

R. Borrow^*, A. J. Fox, D. M. Jones

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

Abstract

Considerable efforts are being made in the search for suitable candidates for an effective serogroup B meningococcal vaccine, but with limited success. We have identified a novel, high molecular weight antigen of approximately 200 kDa. The antigen was expressed during invasive disease as 100% of convalescent case sera contained antibody compared with approximately 50% of carriers. Many clinical isolates did not appear to express the 200 kDa antigen, but corresponding sera contained antibody, indicating in vivo expression. Antibody to this antigen cross-reacted with meningococci of diverse phenotypes. Further investigation of this antigen is required to determine its potential as a future vaccine component.

Original language	English
Pages (from-to)	179-184
Number of pages	6
Journal	Serodiagnosis and Immunotherapy in Infectious Disease
Volume	8
Issue number	3-4
DOIs	https://doi.org/10.1016/S0888-0786(96)01075-X
Publication status	Published - Jan 1997
Externally published	Yes

Bibliographical note

Funding Information:
This study was funded by the Medical Research Council. UK. grant number SPG 911663 1.

Keywords

High molecular weight protein
Meningococcal
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0888-0786(96)01075-X

Cite this

@article{29e8542d81e4434aad6fbceea126b90e,

title = "The immune response to a meningococcal 200 kDa surface exposed protein following carriage and disease",

abstract = "Considerable efforts are being made in the search for suitable candidates for an effective serogroup B meningococcal vaccine, but with limited success. We have identified a novel, high molecular weight antigen of approximately 200 kDa. The antigen was expressed during invasive disease as 100% of convalescent case sera contained antibody compared with approximately 50% of carriers. Many clinical isolates did not appear to express the 200 kDa antigen, but corresponding sera contained antibody, indicating in vivo expression. Antibody to this antigen cross-reacted with meningococci of diverse phenotypes. Further investigation of this antigen is required to determine its potential as a future vaccine component.",

keywords = "High molecular weight protein, Meningococcal, Vaccine",

author = "R. Borrow and Fox, {A. J.} and Jones, {D. M.}",

note = "Funding Information: This study was funded by the Medical Research Council. UK. grant number SPG 911663 1.",

year = "1997",

month = jan,

doi = "10.1016/S0888-0786(96)01075-X",

language = "English",

volume = "8",

pages = "179--184",

journal = "Serodiagnosis and Immunotherapy in Infectious Disease",

issn = "0888-0786",

publisher = "Academic Press Inc.",

number = "3-4",

}

TY - JOUR

T1 - The immune response to a meningococcal 200 kDa surface exposed protein following carriage and disease

AU - Borrow, R.

AU - Fox, A. J.

AU - Jones, D. M.

N1 - Funding Information: This study was funded by the Medical Research Council. UK. grant number SPG 911663 1.

PY - 1997/1

Y1 - 1997/1

N2 - Considerable efforts are being made in the search for suitable candidates for an effective serogroup B meningococcal vaccine, but with limited success. We have identified a novel, high molecular weight antigen of approximately 200 kDa. The antigen was expressed during invasive disease as 100% of convalescent case sera contained antibody compared with approximately 50% of carriers. Many clinical isolates did not appear to express the 200 kDa antigen, but corresponding sera contained antibody, indicating in vivo expression. Antibody to this antigen cross-reacted with meningococci of diverse phenotypes. Further investigation of this antigen is required to determine its potential as a future vaccine component.

AB - Considerable efforts are being made in the search for suitable candidates for an effective serogroup B meningococcal vaccine, but with limited success. We have identified a novel, high molecular weight antigen of approximately 200 kDa. The antigen was expressed during invasive disease as 100% of convalescent case sera contained antibody compared with approximately 50% of carriers. Many clinical isolates did not appear to express the 200 kDa antigen, but corresponding sera contained antibody, indicating in vivo expression. Antibody to this antigen cross-reacted with meningococci of diverse phenotypes. Further investigation of this antigen is required to determine its potential as a future vaccine component.

KW - High molecular weight protein

KW - Meningococcal

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=0030889122&partnerID=8YFLogxK

U2 - 10.1016/S0888-0786(96)01075-X

DO - 10.1016/S0888-0786(96)01075-X

M3 - Article

AN - SCOPUS:0030889122

SN - 0888-0786

VL - 8

SP - 179

EP - 184

JO - Serodiagnosis and Immunotherapy in Infectious Disease

JF - Serodiagnosis and Immunotherapy in Infectious Disease

IS - 3-4

ER -

The immune response to a meningococcal 200 kDa surface exposed protein following carriage and disease

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this